Effect of different dipeptidyl peptidase-4 inhibitors on lipid profile of type II diabetic patients

T. Z. Omran; G. L. Ismaeel

doi:10.53730/ijhs.v6nS2.5229

Authors

Omran T. Z.
tukafaji@alameed.edu.iq
College of pharmacy, University of Al-Ameed, Karbala, Iraq
Ismaeel G. L. College of pharmacy, University of Al-Ameed, Karbala, Iraq

Keywords:

cholesterol level, diabetes mellitus, lipid profile, metformin, vildagliptin

Abstract

Objective: In this research study, we aimed to study the effect of dipeptidyl peptidase-4 inhibitors (Gliptins drug) on the lipid profile of diabetic type 2 patients. Materials/methods: Type 2 diabetic (200) patients taking Gliptin ± metformin and willing to participate in the study were included. Lipid profile tests (total cholesterol, HDL, non-HDL, LDL, VLDL, triglycerides level) of the patients were done in a pathological laboratory on routine health checkups. The mean and S.E.M of each parameter were calculated. All data were subjected to a Student's t-test. Comparison between the treatments was done by using one-way ANOVA- Bonferroni multiple comparison tests. Results: All 200 patients have completed the questionnaire and monitored twice for six months (initial visit and final visit). Of the total participants, 109 (54.50%) were males and 91 (45.50%) were females. Ninety tow (46%) were taking vildagliptin + metformin while 73 (36.5%) patients were taking vildagliptin, 20 (10%) were taking sitagliptin + metformin, 15 (7.5%) were taking linagliptin and only 1 (0.5%) patients were taking sitagliptin. Conclusions: The present findings showed that vildagliptin can reduce the total cholesterol level, Non-HDL level, and triglycerides significantly. Linagliptin can reduce the total cholesterol Level and non-HDL significantly.

Downloads

Download data is not yet available.

References

Ashour FA, Al-Gazally ME, Alshok MM. Association between Lipoprotein Lipase Polymorphism and the Myocardial Infarction in Patients with Diabetes Mellitus Type 2. Indian Journal of Public Health Research & Development. 2019;10(2).

Mota RI, Morgan SE, Bahnson EM. Diabetic vasculopathy: macro and microvascular injury. Current pathobiology reports. 2020;8(1):1-14.

Rosen CJ, Ingelfinger JR. Traveling down the long road to type 1 diabetes mellitus prevention. N Engl J Med. 2019;381(7):666-7.

Mohammed NJ, Ali MEA-GM, Awadh A. Evaluation The Serum Total Protein in Patients with Diabetes Mellitus (Type I and Type II) and Study Genetic Level of Glutathione-S-Transferaseµ. Medical Journal of Babylon. 2015;12(3):625-31.

Forbes JM, Cooper ME. Mechanisms of diabetic complications. Physiological reviews. 2013;93(1):137-88.

DeFronzo RA, Ferrannini E, Groop L, Henry RR, Herman WH, Holst JJ, et al. Type 2 diabetes mellitus. Nature reviews Disease primers. 2015;1(1):1-22.

Avogaro A, Giorda C, Maggini M, Mannucci E, Raschetti R, Lombardo F, et al. Incidence of coronary heart disease in type 2 diabetic men and women: impact of microvascular complications, treatment, and geographic location. Diabetes care. 2007;30(5):1241-7.

Gæde P, Lund-Andersen H, Parving H-H, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. New England Journal of Medicine. 2008;358(6):580-91.

Monami M, Vitale V, Ambrosio ML, Bartoli N, Toffanello G, Ragghianti B, et al. Effects on Lipid Profile of Dipeptidyl Peptidase 4 Inhibitors, Pioglitazone, Acarbose, and Sulfonylureas: Meta-analysis of Placebo-Controlled Trials. Advances in Therapy. 2012;29(9):736-46.

Ceriello A, Colagiuri S. International Diabetes Federation guideline for management of postmeal glucose: a review of recommendations. Diabetic Medicine. 2008;25(10):1151-6.

Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK. Cardiovascular risk factors in confirmed prediabetic individuals: does the clock for coronary heart disease start ticking before the onset of clinical diabetes? Jama. 1990;263(21):2893-8.

Verges B. Dyslipidaemia in diabetes mellitus. Review of the main lipoprotein abnormalities and their consequences on the development of atherogenesis. Diabetes & metabolism. 1999;25:32-40.

Makrilakis K. The role of DPP-4 inhibitors in the treatment algorithm of type 2 diabetes mellitus: when to select, what to expect. International journal of environmental research and public health. 2019;16(15):2720.

Holst JJ. From the incretin concept and the discovery of GLP-1 to today's diabetes therapy. Frontiers in endocrinology. 2019;10:260.

Gómez-Huelgas R, Peralta FG, Mañas LR, Formiga F, Domingo MP, Bravo JM, et al. Treatment of type 2 diabetes mellitus in elderly patients. Revista Clínica Española (English Edition). 2018;218(2):74-88.

Heise T. The future of insulin therapy. Diabetes Research and Clinical Practice. 2021;175:108820.

Kaku K, Kisanuki K, Shibata M, Oohira T. Benefit-risk assessment of alogliptin for the treatment of Type 2 diabetes mellitus. Drug safety. 2019;42(11):1311-27.

Davis H, Jones Briscoe V, Dumbadze S, Davis SN. Using DPP-4 inhibitors to modulate beta cell function in type 1 diabetes and in the treatment of diabetic kidney disease. Expert opinion on investigational drugs. 2019;28(4):377-88.

Scheen AJ. A review of gliptins for 2014. Expert opinion on pharmacotherapy. 2015;16(1):43-62.

Scheen AJ. The safety of gliptins: updated data in 2018. Expert opinion on drug safety. 2018;17(4):387-405.

Kusunoki M, Sato D, Nakamura T, Oshida Y, Tsutsui H, Natsume Y, et al. DPP-4 Inhibitor Teneligliptin Improves Insulin Resistance and Serum Lipid Profile in Japanese Patients with Type 2 Diabetes. Drug Res (Stuttg). 2015;65(10):532-4.

Monami M, Lamanna C, Desideri CM, Mannucci E. DPP-4 Inhibitors and Lipids: Systematic Review and Meta-Analysis. Advances in Therapy. 2012;29(1):14-25.

Tang Y-Z, Wang G, Jiang Z-H, Yan T-T, Chen Y-J, Yang M, et al. Efficacy and safety of vildagliptin, sitagliptin, and linagliptin as add-on therapy in Chinese patients with T2DM inadequately controlled with dual combination of insulin and traditional oral hypoglycemic agent. Diabetology & Metabolic Syndrome. 2015;7(1):91.

Fox CS, Golden SH, Anderson C, Bray GA, Burke LE, de Boer IH, et al. Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association. Circulation. 2015;132(8):691-718.

Cha S-A, Park Y-M, Yun J-S, Lim T-S, Song K-H, Yoo K-D, et al. A comparison of effects of DPP-4 inhibitor and SGLT2 inhibitor on lipid profile in patients with type 2 diabetes. Lipids in Health and Disease. 2017;16(1):58.